Menopause symptoms, and which ones the label actually treats

Hot flashes and night sweats

What is known. Vasomotor symptoms are the clinical name for hot flashes or night sweats, and they carry more trial data than anything else on this page because they are the endpoint the approved drugs were tested against. SWAN followed 3,302 women and analysed the 1,449 who reported frequent episodes. Median total duration was 7.4 years, and median persistence after the final menstrual period was 4.5 years. A median means half of women ran longer.

Is hormone therapy indicated for it. Yes, and it is the first line the label prints: “Treatment of moderate to severe vasomotor symptoms associated with the menopause.” The 2022 hormone therapy position statement of The North American Menopause Society states it plainly as well: Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. The same statement scopes who that applies to: For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss.

What else has evidence. Two FDA-approved non-hormonal drugs treat the same endpoint, fezolinetant and elinzanetant, and one SSRI carries a vasomotor indication. Each brings its own monitoring burden, and 2 of the three carry a boxed warning: fezolinetant for hepatotoxicity, the SSRI for suicidal thoughts and behaviors. That is the part the marketing skips. The non-hormonal class, compared label by label.

One measured finding worth carrying into the next two sections. Across 58 symptoms tracked in 3,289 SWAN participants over 16 years, vasomotor symptoms tended to cluster with sleep disturbances and fatigue, were present in each of the moderate to highly symptomatic classes, but were not a defining characteristic of the symptom clusters. Hot flashes travel with sleep loss and exhaustion, and that association is what every indirect claim further down this page rests on.

Vaginal dryness, painful sex and urinary symptoms

What is known. The staging system puts these symptoms at a different point on the timeline from hot flashes, in two of its own sentences. Of early postmenopause, the first two years after the final menstrual period, STRAW + 10 writes: “Symptoms, most notably vasomotor symptoms, are most likely to occur during this stage.” Of late postmenopause, it writes that “Symptoms of vaginal dryness and urogenital atrophy become increasingly prevalent at this time”. Hot flashes peak early and fade for most women. Genitourinary symptoms become more common the further past menopause you are, which changes what waiting costs you.

Is hormone therapy indicated for it. Yes, and the label points you at a different product. Indication two on the systemic tablet reads: “Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause.” The same label adds that when prescribing solely for that, topical vaginal products should be considered. The Menopause Society names genitourinary syndrome of menopause alongside vasomotor symptoms in the sentence quoted above.

Where the wording gets narrower than the marketing. The approved vaginal estrogen labels are worded around vulvar and vaginal atrophy. Urinary urgency and recurrent urinary tract infection sit inside genitourinary syndrome of menopause as clinicians describe it, and of the 4 approved vaginal estrogen labels we read, 0 name a urinary indication. That gap is worth knowing before a platform sells you the product for a bladder symptom. Vaginal estrogen, label by label and priced. Of the 13 women's-wing platforms we track, 5 list a vaginal estradiol form in their published formulary.

Brain fog, word-finding and concentration

What is known, and it is more reassuring than the category usually admits. SWAN administered cognitive tests to 2,362 women over 4 years and found that perimenopause was associated with a decrement in cognitive performance, characterized by women not being able to learn as well as they had during premenopause. Then it found the other half: Improvement rebounded to premenopausal levels in postmenopause, suggesting that menopause transition-related cognitive difficulties may be time-limited.The authors wrote “suggesting” and “may be”, and this page keeps both words, because a longitudinal cohort establishes the pattern rather than proving the mechanism.

Is hormone therapy indicated for it.No. No form of the word cognitive appears on the estradiol label. The word memory appears five times and all five are the proper name of the Women's Health Initiative Memory Study, which is on the label as a risk rather than a benefit: in 4,532 postmenopausal women aged 65 and older taking conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg, probable dementia ran 45 per 10,000 women-years against 22 per 10,000 women-years on placebo over an average of 4 years, a relative risk of 2.05 (95% CI, 1.21 to 3.48).

What else has evidence.The indirect route is the honest one. If night sweats are waking you repeatedly, then treating the night sweats is a labelled use of the drug and thinking more clearly the next morning is a consequence of having slept. That is a real reason to treat, and it is a different claim from “estrogen fixes brain fog”. SWAN also observed that starting hormones before the final menstrual period tracked with better performance and starting after tracked with worse, which is an observational signal about timing rather than a trial result and should be read as one.

Fatigue and no energy

Is hormone therapy indicated for it. No, and the absence is total. Fatigue, tired, sleep and insomnia each appear zero times on the estradiol label. There is no indication, no adverse reaction entry, and no rate to quote in either direction.

What is known, and this is the finding that changes what you do on Monday. SWAN linked daily menstrual calendars to annual symptom reports in 2,329 women and asked whether heavy or prolonged bleeding tracked with fatigue. Reporting three or more episodes of heavy menstrual bleeding in the prior 6 months was associated with feeling tired at an odds ratio of 1.62 (95% CI 1.11 to 2.38). The second fatigue measure, being worn out, came in at 1.44 (95% CI 0.98 to 2.13), an interval that includes 1. Three or more episodes of prolonged bleeding was associated with lower odds of being full of pep, 0.68 (95% CI 0.49 to 0.95).

Models were adjusted for race and ethnicity, age, body mass index, hormone therapy use, depressive and anxiety symptoms, perceived stress, sleep problems, cigarette use, and discrimination. Read the intervals rather than the point estimates: one of the three includes 1, which means that result on its own is compatible with no effect, and this page says so rather than rounding it into the headline the way a press summary would.

What else has evidence. The indirect route again: fatigue clustered with vasomotor symptoms and sleep disturbance in the SWAN clustering analysis, so treating night sweats that are waking you is a labelled use with a plausible downstream effect on how you feel. Beyond that, the honest answer is that fatigue is a symptom with many causes and menopause is one candidate among several. The perimenopause hub covers the look-alikes worth excluding. Perimenopause, diagnosis and what gets mistaken for it.

Hair thinning and hair loss

What is known, with the scope attached. The best single prevalence figure we could verify is 52.2 percent (95% CI 44.6 to 59.8) of 178 postmenopausal women aged 50 to 65 showing female pattern hair loss, from a single cross-sectional study at one hospital in Bangkok, graded from standardised photography by three dermatologists. One study, one clinic, one population. It is not a US population estimate and we are not going to dress it as one.

Is hormone therapy indicated for it.No, and the label runs the other way. Hair appears twice on the estradiol label and both times it is a side effect: “Loss of scalp hair” under Adverse Reactions in the Skin group, alongside “Hirsutism”, and “Hair loss” in the side effect list of the patient leaflet. Those entries carry no rate on this label, so nobody can tell you how often either happens from this source.

What else has evidence.Topical minoxidil 5 percent holds an over-the-counter labelled indication for women. Its stated purpose is “Hair regrowth treatment for women” and its use is “Use to regrow hair on the top of the scalp”. The label is unusually candid about its own limits, and those sentences are worth reading before you buy it:

• “This product will not work for all women.”
• “Results may occur at 3 months with once daily use. For some women, you may need to use this product once a day for at least 6 months before you see results.”
• “continued use is necessary to increase and keep your hair regrowth, or hair loss will begin again”

Do not use if your hair loss is sudden and/or patchy, or if you do not know the reason for your hair loss. Read from the Women's Rogaine 5% minoxidil topical foam label, SPL effective 2024-11-13.

Menopause belly and central weight gain

Is hormone therapy indicated for it. No, and the label is unusually blunt about it. Weight appears 4 times across the whole document. Two of those recommend weight-bearing exercise against osteoporosis. One is the word overweight, in a list of things that raise your chances of heart disease. The fourth is in Adverse Reactions and reads “Increase or decrease in weight”, naming both directions, with no rate attached to either. There is no weight indication among the 6 the label prints.

What is known. The randomized record on hormone therapy and weight is small and mixed, and the body-composition question is separate from the scale question. Both take a full page with every confidence interval attached, so we gave them one rather than compressing them into a paragraph here. HRT and weight loss, with the whole trial table is the section of this site that answers it.

Am I in perimenopause? The two thresholds that answer it

There is a published staging system and it starts with your calendar. STRAW + 10 was held in Washington, DC, on September 20 and 21, 2011, sponsored by the National Institute on Aging and the Office of Research on Women's Health of the National Institutes of Health, The North American Menopause Society, the American Society for Reproductive Medicine, the International Menopause Society, and the Endocrine Society, and it defines each stage by what your cycles are doing. Two of its thresholds are specific enough to check tonight.

If those two definitions describe your last year, you have the answer most people are paying for a test to get, and the next step the staging system points at is a treatment conversation. Score your symptoms on the Menopause Rating Scale, which is a published and validated instrument rather than a quiz we invented, and take the result to the appointment. Then the perimenopause hub covers age of onset, duration and what to expect across the transition.

What an FSH level can and cannot tell you

The single most useful sentence on this subject is a parenthetical in STRAW + 10, and here is the decision it came out of. The workshop resolved to “consider menstrual cycle criteria to remain the most important criteria given the continuing lack of international standardization of biomarker assays as well as their cost and/or invasiveness”, and then to “consider biomarker criteria as supportive criteria given the lack of assay standardization (supportive criteria are to be used only as necessary and should not be interpreted as required for diagnosis)”

Read the words inside the parentheses twice. Supportive criteria, used only as necessary, and explicitly not required for diagnosis. That is the published position of the group that wrote the staging system, and it is why a clinician who rules perimenopause out on one normal FSH is working against the framework rather than from it.

Where a level does earn its place.When the bleeding criteria are unavailable, after a hysterectomy for instance, staging has to fall back on the endocrine markers, and STRAW + 10 says even then that “A single sample for measurement of FSH and estradiol may be ambiguous or misleading, and at least one repeated measurement is often required.” One draw, one conclusion, is the pattern the source warns against in the exact case where a draw is the only tool left. Under 40, or with absent periods and other possible causes, labs do real work, and that is a different question from confirming a transition your calendar already shows.

Source: Stages of Reproductive Aging Workshop + 10 executive summary, full text, Harlow et al, J Clin Endocrinol Metab 2012;97:1159-1168. Every quotation above was read from that document on August 16, 2026.

The one genuine red flag on this page: bleeding

Everything above is a comfort and function question. This section is not. Cycle changes are the defining feature of the transition and some bleeding patterns need an appointment rather than a symptom tracker. ACOG publishes the list, and these are its five items verbatim:

Bleeding after menopause, with both numbers

Any bleeding after 12 months without a period is the item on that list that carries the most weight, and the honest way to explain why is to publish both halves of the evidence. A meta-analysis of 129 studies covering 34,432 women with postmenopausal bleeding and 6,358 with endometrial cancer found:

The authors' own conclusion on the second number, with PMB their abbreviation for postmenopausal bleeding: “most women with PMB will not be diagnosed with endometrial cancer”. Both figures belong on the page. The first is the reason to book the appointment this week. The second is the reason you can book it without spending the intervening days convinced of the worst. Clarke et al, JAMA Internal Medicine 2018.